摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methyl-3,4-di(benzyloxy)pyridine | 127234-69-9

中文名称
——
中文别名
——
英文名称
2-methyl-3,4-di(benzyloxy)pyridine
英文别名
2-methyl-3,4-dibenzyloxypyridine;2-Methyl-3,4-bis(phenylmethoxy)pyridine;2-methyl-3,4,bis(phenylmethoxy)pyridine;3,4-Bis(benzyloxy)-2-methylpyridine
2-methyl-3,4-di(benzyloxy)pyridine化学式
CAS
127234-69-9
化学式
C20H19NO2
mdl
——
分子量
305.376
InChiKey
LGJIGJOMCGETHF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    447.1±40.0 °C(Predicted)
  • 密度:
    1.137±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    23
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
    申请人:E.R. Squibb & Sons, Inc.
    公开号:EP0336369A1
    公开(公告)日:1989-10-11
    Compounds having the formula and pharmaceutically acceptable salts thereof, exhibit antibacterial activity. R is
    具有以下化学式的化合物及其药用盐具有抗菌活性。R 是
  • Monobactam hydrazide derivatives
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US05112968A1
    公开(公告)日:1992-05-12
    Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof which possess antibacterial activity. R.sub.s is a substituted hydroxy pyridone of the formulae: ##STR2## wherein Y.sub.1 is CH.sub.2 X; COOR.sub.6 ; CONR.sub.7 R.sub.8 ; OH; OCH.sub.2 R.sub.9 ; CHF.sub.2 ; CHO; CH.dbd.N--OR.sub.10 ; CH.dbd.CH--R.sub.11 ; CN; CH.dbd.N--NHR.sub.12, and Y.sub.2 is hydrogen; COOH; CONH.sub.2 ; CN; CSNH.sub.2 ; COO lower alkyl; CONR.sub.7 /R.sub.8.
    具有以下式##STR1##及其药学上可接受的盐的化合物具有抗菌活性。R.sub.s是以下式的取代羟基吡啶:##STR2##其中Y.sub.1是CH.sub.2 X;COOR.sub.6;CONR.sub.7 R.sub.8;OH;OCH.sub.2 R.sub.9;CHF.sub.2;CHO;CH.dbd.N--OR.sub.10;CH.dbd.CH--R.sub.11;CN;CH.dbd.N--NHR.sub.12,Y.sub.2是氢;COOH;CONH.sub.2;CN;CSNH.sub.2;COO较低烷基;CONR.sub.7 /R.sub.8。
  • Iron Modulators
    申请人:Hider Robert Charles
    公开号:US20080200520A1
    公开(公告)日:2008-08-21
    Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R 1 is selected from H, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 hydroxyalkyl, C 1-6 hydroxyalkenyl, R 2 is selected from H, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 hydroxyalkyl, C 1-6 hydroxyalkenyl and C 6-10 aralykyl in which the aryl group of the aralkyl group is optionally substituted by hydroxy, halo or C1-4 alkyl R 3 is selected from H, C 1-6 alkyl, C 1-6 alkenyl and C 1-12 acyl; R 4 is selected from H and C 1-3 alkyl R 5 , R 6 and R 7 are independently selected from H, C 1-6 alkyl, C 3-7 aryl, and C 1-10 aralkyl; the alkyl, aryl and aralkyl groups being optionally substituted by one or more halo, hydroxy and nitro groups or R 5 and R 7 together with the nitrogen atom to which they are bonded form a heterocyclic ring optionally substituted by one or more hydroxyl groups or a pharmaceutically acceptable tautomer, ester or addition salt thereof.
    提供公式(I)的铁调节剂化合物,用于治疗淀粉样病,其中R1选择自H,C1-6烷基,C1-6烯基,C1-6羟基烷基,C1-6羟基烯基,R2选择自H,C1-6烷基,C1-6烯基,C1-6羟基烷基,C1-6羟基烯基和C6-10芳基烷基,其中芳基烷基的芳基基团可选择性地被羟基,卤素或C1-4烷基取代,R3选择自H,C1-6烷基,C1-6烯基和C1-12酰基; R4选择自H和C1-3烷基,R5,R6和R7独立选择自H,C1-6烷基,C3-7芳基和C1-10芳基烷基; 烷基,芳基和芳基烷基可以选择性地被一个或多个卤素,羟基和硝基基团取代,或者R5和R7与它们连接的氮原子共同形成一个杂环环,该杂环环可以选择性地被一个或多个羟基取代,或其药学上可接受的互变异构体,酯或加成盐。
  • Synthesis, physical–chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer’s disease
    作者:Alessandra Gaeta、Francisco Molina-Holgado、Xiao L. Kong、Sarah Salvage、Sarah Fakih、Paul T. Francis、Robert J. Williams、Robert C. Hider
    DOI:10.1016/j.bmc.2010.12.007
    日期:2011.2
    A novel class of 2-amido-3-hydroxypyridin-4-one iron chelators is described. These compounds have been designed to behave as suitable molecular probes which will improve our knowledge of the role of iron in neurodegenerative conditions. Neurodegenerative disorders, such as Alzheimer's disease (AD) and Parkinson disease (PD), can be considered as diverse pathological conditions sharing critical metabolic processes such as protein aggregation and oxidative stress. Interestingly, both these metabolic alterations seem to be associated with the involvement of metal ions, including iron. Iron chelation is therefore a potential therapeutic approach. The physico-chemical (pK(a) pFe(3+) and log P) and biological properties (inhibition of iron-containing enzymes) of these chelators have been investigated in order to obtain a suitable profile for the treatment of neurodegenerative conditions. Studies with neuronal cell cultures confirm that the new iron chelators are neuroprotective against beta-amyloid-induced toxicity. (C) 2010 Elsevier Ltd. All rights reserved.
  • WO2006/103463
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多